CANF

Can Fite BioPharma (CANF)

Can Fite BioPharma Ltd

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:AMEX:CANF

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/03/03	20 : 04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2025/03/03	20 : 00	GlobeNewswire Inc.	Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits	AMEX:CANF	Can Fite BioPharma Ltd
2025/02/18	21 : 04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2025/02/18	21 : 00	GlobeNewswire Inc.	Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson	AMEX:CANF	Can Fite BioPharma Ltd
2025/02/15	07 : 33	Edgar (US Regulatory)	Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	AMEX:CANF	Can Fite BioPharma Ltd
2025/02/10	21 : 10	GlobeNewswire Inc.	Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25	AMEX:CANF	Can Fite BioPharma Ltd
2025/02/05	21 : 02	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2025/02/05	21 : 00	GlobeNewswire Inc.	Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025	AMEX:CANF	Can Fite BioPharma Ltd
2025/01/27	21 : 03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2025/01/27	21 : 00	GlobeNewswire Inc.	US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug	AMEX:CANF	Can Fite BioPharma Ltd
2024/12/30	21 : 01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2024/12/30	21 : 00	GlobeNewswire Inc.	Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson	AMEX:CANF	Can Fite BioPharma Ltd
2024/12/04	21 : 05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2024/12/04	21 : 00	GlobeNewswire Inc.	8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug	AMEX:CANF	Can Fite BioPharma Ltd
2024/11/15	06 : 48	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	AMEX:CANF	Can Fite BioPharma Ltd
2024/11/11	21 : 00	GlobeNewswire Inc.	Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial	AMEX:CANF	Can Fite BioPharma Ltd
2024/11/04	21 : 09	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2024/11/04	21 : 08	GlobeNewswire Inc.	Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia	AMEX:CANF	Can Fite BioPharma Ltd
2024/10/18	22 : 23	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2024/10/18	22 : 06	GlobeNewswire Inc.	Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson	AMEX:CANF	Can Fite BioPharma Ltd
2024/10/09	20 : 03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2024/10/09	20 : 00	GlobeNewswire Inc.	FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer	AMEX:CANF	Can Fite BioPharma Ltd
2024/10/07	20 : 00	GlobeNewswire Inc.	Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29	AMEX:CANF	Can Fite BioPharma Ltd
2024/09/24	20 : 05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2024/09/24	20 : 00	GlobeNewswire Inc.	Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis	AMEX:CANF	Can Fite BioPharma Ltd
2024/09/16	20 : 07	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2024/09/16	20 : 00	GlobeNewswire Inc.	Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health	AMEX:CANF	Can Fite BioPharma Ltd
2024/09/09	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	AMEX:CANF	Can Fite BioPharma Ltd
2024/09/07	05 : 30	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	AMEX:CANF	Can Fite BioPharma Ltd
2024/09/06	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	AMEX:CANF	Can Fite BioPharma Ltd